Innate Pharma Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Innate Pharma Sa (IPHA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Innate Pharma Sa vs Its Competitors
- TTM: Trailing 12-month revenue of 10M vs 282,937M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+71.7%) for its tracked peer group.
- Growth: Innate Pharma Sa generated -55.3% revenue growth year over year in Q4 2025, vs 9.9% for its tracked competitors combined.
- Profitability: Its -546.1% net margin compares with 15.3% for the peer group.
- Scale: Innate Pharma Sa ranks #98 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer revenue share: Innate Pharma Sa accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.06M compares with $1.12M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IPHA Sales vs. its Competitors, Q4 2025
Innate Pharma Sa reported revenue contraction of 55.25 % year on year in Q4 2025, below its competitors' combined revenue growth of 9.85 %.
With a net margin of -546.11 %, Innate Pharma Sa reported lower profitability than its competitors (15.25 %).
Innate Pharma Sa generated 0.01 % of the combined sales of its peer group, down from 0.02 % a year earlier.
Innate Pharma Sa vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Innate Pharma Sa and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Innate Pharma Sa | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Innate Pharma Sa's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -55.3% for Innate Pharma Sa. Innate Pharma Sa's share of combined industry revenue moved from 0.06% to 0.02%, a loss of 0.04 percentage points.
Innate Pharma Sa's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Innate Pharma Sa | - | No | No | Yes |
| Competitors combined (58) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IPHA Stock Performance relative to its Competitors
IPHA Stock Performance relative to High-Confidence Competitors
IPHA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Revolution Medicines Inc | 282.9% | Outperformed |
| 3 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Innate Pharma Sa's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Innate Pharma Sa's Comment on Competition and Industry Peers
Publicly Traded Peers of Innate Pharma Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Innate Pharma Sa | 152.30 | 10.09 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| SUBTOTAL | 1,497,105.93 | 282,972.93 |
Sign in to see all competitors of Innate Pharma Sa.
Sources: Innate Pharma Sa's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Innate Pharma Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Innate Pharma Sa's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nkgen Biotech Inc | Named by the company | 85% |
| Corbus Pharmaceuticals | Named by the company | 85% |
| IMAB | Named by the company | 85% |
| Adlai Nortye Ltd | Named by the company | 85% |
| Eli Lilly | Named by the company | 85% |
| Astellas Pharma | Named by the company | 85% |
| Soligenix inc | Named by the company | 85% |
| Aptevo Therapeutics Inc | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Innate Pharma Sa's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Innate Pharma Sa's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Innate Pharma Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Innate Pharma Sa | 152 | 55,722 | -304,300 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| PEERS TOTAL | 1,496,954 | 1,115,160 | 116,040 |
Innate Pharma Sa's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Exelixis Inc | United States 91.44 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Innate Pharma Sa's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Innate Pharma Sa's industry classification, broader than the peer set above. Market cap in millions of $.Innate Pharma Sa ranks #98 of 159 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 98 | Innate Pharma Sa | 143 | 0.02 % |
Market cap and industry share for the rest of Innate Pharma Sa's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-25.
Innate Pharma Sa's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 93 | Acumen Pharmaceuticals Inc | 160 | 49.32 % |
| 94 | Voyager Therapeutics Inc | 158 | -36.19 % |
| 95 | Precision Biosciences Inc | 156 | 22.12 % |
| 96 | Cellectis S a | 145 | -56.33 % |
| 97 | Cardiol Therapeutics inc | 1,234 | 12.3% |
| 98 | Innate Pharma Sa | 143 | -9.24 % |
| 99 | Entera Bio Ltd | 1,234 | 12.3% |
| 100 | Engene Therapeutics Inc | 1,234 | 12.3% |
| 101 | Tenaya Therapeutics Inc | 1,234 | 12.3% |
| 102 | Humacyte Inc | 1,234 | 12.3% |
| 103 | Neumora Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Innate Pharma Sa's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Innate Pharma Sa's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 68.46 % (avg) | -68.5 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -0.94 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 1.55 % | 6.74 % (avg) | -5.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Innate Pharma Sa's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 6.88 % | -67.36 % | -55.25 % |
| Operating Margin | -20.55 % | - | - |
| Return on Invested Capital | -9.09 % | -120.90 % | 280.82 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Innate Pharma Sa's BCG Growth-Share Matrix
Relative market share (vs Innate Pharma Sa's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Innate Pharma Sa falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Innate Pharma Sa's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.55 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Innate Pharma Sa's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Innate Pharma Sa's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Innate Pharma Sa's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Innate Pharma Sa falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Innate Pharma Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 216.1 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (45.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Innate Pharma Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Innate Pharma Sa | 0.77 | 1.27 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Innate Pharma Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Innate Pharma Sa | Q4 2025 | -55.2 % | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| PEERS TOTAL | +11.6 % | -69.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Innate Pharma Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Innate Pharma Sa | Q4 2025 | - | -64.2 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
Innate Pharma Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Innate Pharma Sa | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Innate Pharma Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Innate Pharma Sa | - | 15.10 |
| Merck and Co Inc | 119.91 | 5.52 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Amgen Inc | 25.97 | 5.97 |
| Gilead Sciences Inc | - | 6.21 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| PEERS AVERAGE | 50.94 | 5.29 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.